

Oct 31, 2025

Transcreener® AMP²/GMP² TR-FRET Assay Technical Manual

DOI

<https://dx.doi.org/10.17504/protocols.io.kqdg31bqpl25/v1>

info¹

¹BellBrook Labs LLC

BellBrook Labs

Tech. support phone: +1 (608) 443-2400 email: techsupport@bellbrooklabs.com



info info

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.kqdg31bqpl25/v1>

Protocol Citation: info 2025. Transcreener® AMP²/GMP² TR-FRET Assay Technical Manual. [protocols.io](https://dx.doi.org/10.17504/protocols.io.kqdg31bqpl25/v1)
<https://dx.doi.org/10.17504/protocols.io.kqdg31bqpl25/v1>

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: October 02, 2025

Last Modified: October 31, 2025

Protocol Integer ID: 228868

Keywords: amp2/gmp2 tr-fret assay, assay development for new hts target, assay development, inhibitor profiling, inhibitor profiling across multiple target family, substrate nucleotide, competitive immunoassay for enzyme, selectivity over substrate nucleotide, assay, specific monoclonal antibody, enzyme, new hts target, phosphodiesterase, protein ligase, throughput screening, gmp, competitive immunoassay, nucleic acid, including atp

Abstract

The Transcreener® AMP²/GMP² TR-FRET Red Assay is a competitive immunoassay for enzymes that produce AMP or GMP with a far-red, time-resolved Förster-resonance-energy-transfer (TR-FRET) readout. The assay relies on a highly specific monoclonal antibody that recognizes AMP or GMP with more than 1,000-fold selectivity over substrate nucleotides, including ATP, cAMP, or cGMP. Enzymes that can be used with the assay include ubiquitin, SUMO, nucleic acid and protein ligases, phosphodiesterases (PDEs), and synthetases.

The Transcreener® assay is designed specifically for high-throughput screening (HTS), with a single-addition, mix-and-read format. It offers reagent stability and compatibility with commonly used multimode plate readers. The generic nature of the Transcreener® HTS assay platform eliminates delays involved in assay development for new HTS targets and greatly simplifies compound and inhibitor profiling across multiple target families.

Introduction

- 1 The Transcreener® AMP²/GMP² TR-FRET Red Assay is a competitive immunoassay for enzymes that produce AMP or GMP with a far-red, time-resolved Förster-resonance-energy-transfer (TR-FRET) readout. The assay relies on a highly specific monoclonal antibody that recognizes AMP or GMP with more than 1,000-fold selectivity over substrate nucleotides, including ATP, cAMP, or cGMP. Enzymes that can be used with the assay include ubiquitin, SUMO, nucleic acid and protein ligases, phosphodiesterases (PDEs), and synthetases.

The Transcreener® assay is designed specifically for high-throughput screening (HTS), with a single-addition, mix-and-read format. It offers reagent stability and compatibility with commonly used multimode plate readers. The generic nature of the Transcreener® HTS assay platform eliminates delays involved in assay development for new HTS targets and greatly simplifies compound and inhibitor profiling across multiple target families.

The Transcreener® AMP²/GMP² TR-FRET Red Assay provides the following benefits:

- Accommodates substrate concentrations ranging from 0.1 μ M to 1,000 μ
- Excellent data quality ($Z' \geq 0.7$) at low substrate conversion (typically 10–30%).
- The only assay method that allows detection of unmodified AMP and GMP without using coupling enzymes.
- Overcomes the need for time-consuming, one-off assay development for individual members within a group transfer enzyme family by using a single set of assay reagents that detect an invariant product.
- Time-gated detection method largely eliminates interference that can result from prompt fluorescence of test compounds.
- Far-red tracer further minimizes interference from fluorescent compounds and light scattering.




Figure 1. Schematic overview of the Transcreener AMP²/GMP² TR-FRET Red Assay. The Transcreener® AMP/GMP Detection Mixture contains an AMP/GMP HiLyte647 tracer bound to an AMP²/GMP² antibody conjugated to terbium (Tb). Excitation of the Tb complex in the UV range (~330 nm) results in energy transfer to the tracer and emission at a higher wavelength (665nm) after a time delay. AMP/GMP produced by the target enzyme displaces the tracer, which causes a decrease in TR-FRET.

Product Specifications

2

	Product	Quantity	Part #
	Transcreener® AMP ² /GMP ² TR-FRET Red Assay	1,000 assays*	3020-1K
		10,000 assays*	3020-10K

*The exact number of assays depends on enzyme reaction conditions. The kits are designed for use with 384-well plates, using 20 µL reaction volumes.

IMPORTANT: Antibody centrifugation is required to remove aggregates that can disrupt data quality. Antibodies should be centrifuged at 10,000 x g for 10 minutes before use. Following centrifugation, pipet the solution needed from the top of the aliquot to ensure precipitate is not present in the detection reagents.

Storage

Store all reagents at -20°C upon receipt.

Materials Provided

2.1

Component	Composition	Notes
AMP/GMP HiLyte647 Tracer	10 μ M solution in 2 mM HEPES (pH 7.5) containing 0.01% Brij-35	The concentration of AMP/GMP HiLyte647 Tracer needed for an enzyme target depends upon the initial ATP/cAMP/cGMP concentration and buffer conditions in the enzyme reaction (see Section 4.2). Sufficient tracer is included in the kit to complete 1,000 assays (Part # 3021-1K) or 10,000 assays (Part # 3021-10K) at an ATP/cAMP/GMP concentration up to 100 μ M.
AMP ² /GMP ² Antibody-Terbium Conjugate	800 nM solution in HEPES-buffered saline	The final antibody concentration in the reaction is 4 nM in a 20 μ L final reaction volume.
Tris Solution	1 M Tris (pH 7.5)	Tris Solution is used to buffer the Detection Mixture.
AMP	5 mM	AMP is used to create an ATP/AMP or cAMP/AMP standard curve.
GMP	5 mM	GMP is used to create a cGMP/GMP standard curve

Note

Caution: AMP and GMP are common reagents in many laboratories; however, it is imperative that highly purified preparations be used for the Transcreener® assay. If the AMP or GMP stocks contain impurities, the assay window will be compromised.

Materials Required but Not Provided

- 2.2
- **Ultrapure Water**—Some deionized water systems are contaminated with nucleases that can degrade both nucleotide substrates and products, reducing assay performance. Careful handling and use of ultrapure water eliminates this potential problem.
 - **Enzyme**—Transcreener® AMP/GMP assays are designed for use with purified enzyme preparations. Contaminating enzymes, such as phosphatases or nucleotidases, can produce background signal and reduce the assay window.
 - **Enzyme Buffer Components**—User-supplied enzyme buffer components include enzyme, enzyme cofactors, substrates, and test compounds.
 - **Plate Reader**—A microplate reader configured to measure TR-FRET of the Tb:HiLyte647 donor:acceptor pair is required. This assay has been designed to provide high-quality data on any HTS-qualified instrument configured to measure TR-FRET using standard europium or terbium complexes with emission wavelengths at 615 nm and 665 nm. Validation was completed using PHERAstar Plus

Ex₃₃₇/Em₆₂₀/Em₆₆₅ (BMG LABTECH) and Envision Ex₃₂₀/ Em₆₁₅/Em₆₆₅ (Perkin Elmer).

- **Assay Plates**—It is important to use assay plates that are entirely white with a nonbinding surface. We recommend Corning® 384-well plates (Cat. # 4513).
- **Liquid Handling Devices**—Use liquid handling devices that can accurately dispense a minimum volume of 2.5 µL into 384-well plates.

Note

Note: Contact BellBrook Labs Technical Service for suppliers and catalog numbers for buffer components, and additional information regarding setup of TR-FRET instruments.

Before You Begin

- 3
 1. Read the entire protocol and note any reagents or equipment needed (see **Section 2.2**).
 2. Check the TR-FRET instrument and verify that it is compatible with the assay being performed (see **Section 4.1**).

Protocol

- 4 The Transcreener® AMP²/GMP² TR-FRET Red Assay protocol consists of 4 steps (**Figure 2**). The protocol was developed for a 384-well format, using a 15 µL enzyme reaction and 20 µL final volume at the time that the plates are read. The use of different densities or reaction volumes will require changes in reagent quantities.




Figure 2. An outline of the procedure. The assay consists of 4 main steps with a mix-and-read format.

Set Up the Instrument

- 4.1 Becoming familiar with ideal instrument settings for TR-FRET is essential to the success of the Transcreener® AMP²/GMP² TR-FRET Red Assay.

4.1.1 Verify That the Instrument Measures TR-FRET

Ensure that the instrument is capable of measuring TR-FRET (not simply fluorescence intensity) of the terbium:HiLyte647 TR-FRET pair (Ex₃₂₀/Em₆₁₅/Em₆₆₅).

Note

Note: A complete list of instruments and instrument-specific application notes can be found online at: <https://www.bellbrooklabs.com/technicalresources/instrument-compatibility>

Contact BellBrook Labs Technical Service if you have questions about settings and filter sets for a specific instrument.

4.1.2 Define the Maximum TR-FRET Window for the Instrument

Measuring high (0% ATP/cAMP/cGMP conversion) and low (100% ATP/cAMP/cGMP conversion) FRET will define the maximum assay window of your specific instrument. Prepare High and Low FRET Mixtures in quantities sufficient to perform at least 6 replicates for each condition.

Use ATP/cAMP/cGMP at 0.75X and AMP/GMP HiLyte647 Tracer at 0.25X concentration in a 20 µL final reaction volume. This mimics the 2-fold dilution when adding an equal volume of detection mixture to an enzyme reaction. As an example, the 1X detection mixture may contain 10 µM ATP/cAMP/cGMP. After adding this to the enzyme reaction, the concentration in the final 20 µL reaction volume would be 7.5 µM.

High FRET Mixture

Prepare the following solution:

	Component	Stock Concentration	Final Concentration	Example: 25 Assays	Your Numbers
	AMP ² /GMP ² Antibody-	800 nM	3 nM	1.9 µL	

	Component	Stock Concentration	Final Concentration	Example: 25 Assays	Your Numbers
	Tb				
	Tris Solution	1 M	18.75 mM	9.4 μ L	
	AMP/GMP HiLyte647 Tracer	10 μ M	15 nM	0.8 μ L	
	ATP/cAMP/cGMP	5 mM	7.5 μ M	0.8 μ L	
	Water			487.3 μ L	
	Total			500.0 μL	

The assay window will depend upon your initial ATP/cAMP/cGMP concentration. These volumes can be adjusted for fewer assays and different ATP/cAMP/cGMP concentrations.

Low FRET Mixture

Prepare the following solution:

	Component	Stock Concentration	Final Concentration	Example: 25 Assays	Your Numbers
	AMP ² /GMP ² Antibody-Tb	800 nM	3 nM	1.9 μ L	
	Tris Solution	1 M	18.75 mM	9.4 μ L	
	AMP/GMP HiLyte647 Tracer	10 μ M	15 nM	0.8 μ L	
	AMP/GMP	5 mM	7.5 μ M	0.8 μ L	
	Water			487.3 μ L	
	Total			500.0 μL	

The assay window will depend upon your initial AMP/GMP concentration. These volumes can be adjusted for fewer assays and different AMP/GMP concentrations.

4.1.3 Measure the TR-FRET

Test the Z' factor and assay window on your instrument by adding 20 μ L of the Low FRET Mixture in

16 wells and 20 μL of High FRET Mixture in 16 wells. Calculate the Z' factor using the equation below; values greater than 0.7 are acceptable.

$$Z' = 1 - \frac{[(3 \times SD_{\text{High FRET Mixture}}) + (3 \times SD_{\text{Low FRET Mixture}})]}{|(\text{mean of High FRET Mixture ratio 665:615}) - (\text{mean of Low FRET Mixture ratio 665:615})|}$$

Note

Caution: Contact BellBrook Labs Technical Service for assistance if the calculated Z' factor is less than 0.7.

Determine the AMP/GMP HiLyte647 Tracer Concentration

- 4.2 The Transcreener® AMP²/GMP² TR-FRET Red Assay requires detection of AMP/GMP in the presence of excess ATP/cAMP/cGMP (assuming initial velocity enzyme reaction conditions) using an antibody with a finite selectivity for the monophosphate vs. the triphosphate or cyclic monophosphate. The concentration of AMP/GMP HiLyte647 tracer determines the total assay window and the AMP/GMP detection range; the amount needed primarily depends upon the initial ATP/cAMP/cGMP concentration in the enzyme reaction.




Figure 3. Linear relationship between [ATP/cAMP/cGMP] and [AMP/GMP Tracer]. The tracer concentration can be calculated using the equation: $y = 3.78x + 22.3$

4.2.1 Calculating the Tracer Amount

As shown in **Figure 3**, the relationship between ATP/cAMP/cGMP and AMP/GMP HiLyte647 Tracer concentrations is linear. (Though shown for up to 100 μM ATP/cAMP/cGMP, the relationship is valid to 1,000 μM .) Therefore, the quantity of AMP/GMP HiLyte647 Tracer for enzyme reactions that use between 0.1 μM and 1,000 μM initial ATP/cAMP/cGMP can be determined using the equation $y = mx + b$, where x = initial [ATP/cAMP/cGMP] (μM) in the 15 μL enzyme reaction, y = [AMP/GMP HiLyte647 Tracer] (nM) in the 5 μL of 1X AMP/GMP Detection Mixture, m (slope) = 3.78, and b (y-intercept) = 22.3. We recommend a final reaction volume of 20 μL .

For example, if you are using 3 μM ATP/cAMP/cGMP in a 15 μL enzyme reaction, the optimal AMP/GMP HiLyte647 Tracer concentration in the 1X GDP Detection Mixture (assuming 5 μL of AMP/GMP Detection Mixture was added to each 15 μL enzyme reaction) would be $(3.78 \times 3) + 22.3 = 33.6$ nM.

4.2.2 Optimizing the Tracer Concentration

Using the AMP/GMP HiLyte647 Tracer concentration calculated using the equation in **Figure 3** will produce excellent results for most users. If it does not produce the results you require, simply optimize the tracer concentration in a stepwise fashion using the AMP/GMP HiLyte647 Tracer concentration (X) from the line as a starting point. Try performing a standard curve (see **Section 7.1**) at $0.5 \times [Y]$, $[Y]$, and $1.5 \times [Y]$ tracer concentrations to find an assay window that suits your needs. See **Section 6** for troubleshooting suggestions.

Optimize the Enzyme Concentration

- 4.3 Perform an enzyme titration to identify the optimal enzyme concentration for the Transcreener® AMP²/GMP² TR-FRET Red Assay. Use enzyme buffer conditions, substrate, and ATP/cAMP/cGMP concentrations that are optimal for your target enzyme and AMP/GMP HiLyte647 Tracer concentration calculated as described in **Section 4.2**. If a compound screen is planned, you should include the library solvent at its final assay concentration. Run your enzymatic reaction at its requisite temperature and time period. Refer to **Section 7.2** for the tolerance of different components for your buffer conditions.

4.3.1 Enzyme Titration Steps

To achieve the most robust assay and a high signal, the quantity of enzyme required to produce a 50–80% change in FRET signal is ideal (EC_{50} to EC_{80}) for screening of large

compound libraries and generating inhibitor dose-response curves (see **Figure 4**). To determine the EC_{80} enzyme concentration, use the following equation:

$$EC_{80} = (80 \div (100 - 80))^{(1 \div \text{hillslope})} \times EC_{50}$$




Figure 4. Enzyme titration curve. The ideal range of enzyme concentrations is shown in red.

Enzyme Assay Controls

The enzyme reaction controls define the limits of the enzyme assay.

Component	Notes
0% ATP/cAMP/cGMP Conversion Control	This control consists of the AMP/GMP Detection Mixture, the enzyme reaction components (without enzyme), and 100% ATP/cAMP/cGMP (0% AMP/GMP). It defines the upper limit of the assay window.
100% ATP/cAMP/cGMP Conversion Control	This control consists of the AMP/GMP Detection Mixture, the enzyme reaction components (without enzyme), and 100% AMP/GMP (0% ATP/cAMP/cGMP). It defines the lower limit of the assay window.

Component	Notes
Minus-Nucleotide Control and Minus-Substrate Control	To verify that the enzyme does not interfere with the detection module, perform an enzyme titration in the absence of nucleotide (i.e., ATP/cAMP/cGMP).
AMP/GMP Standard Curve	Although optional, an AMP/GMP standard curve can be useful to ensure day-to-day reproducibility and that the assay conditions were performed using initial rates. It can also be used to calculate product formed and inhibitor IC ₅₀ values. See Section 7.1 for a description of how to run the standard curve.
Background Control	Use only 0.5X enzyme reaction conditions and Tris Solution.

Run an Assay

- 4.4
1. Add the enzyme reaction mixture to test compounds and mix on a plate shaker.
 2. Start the reaction by adding ATP/cAMP/cGMP, then mix. The final volume of the enzyme reaction mixture should be 15 µL. Incubate at a temperature and time ideal for the enzyme target before adding the AMP/GMP Detection Mixture.
 3. Prepare 1X AMP/GMP Detection Mixture as follows:

ATP Concentration: Examples

Component	1 µM	10 µM	100 µM	Your Numbers
AMP ² /GMP ² Antibody-Tb	100 µL	100 µL	100 µL	
AMP/GMP HiLyte647 Tracer	13.1 µL	30.1 µL	200.2 µL	
Tris Solution (1 M)	125 µL	125 µL	125 µL	
Water	4,762.0 µL	4745.0 µL	4574.8 µL	
Total	5,000 µL	5,000 µL	5,000 µL	

Final concentrations in the detection mixture should be 16 nM AMP²/GMP² Antibody-Tb, 25 mM Tris Solution, and the tracer concentration calculated using the equation in Figure 3. An example is shown below:

$$y = 3.78x + 22.3$$



	A	B	C	D
	ATP	1 μ M	10 μ M	100 μ M
	AMP/GMP HiLyte647 Tracer	26.1 nM	60.1 nM	400.3 nM

4. Add 5 μ L of 1X AMP/GMP Detection Mixture to 15 μ L of the enzyme reaction. Mix using a plate shaker.
5. Incubate at room temperature (20–25°C) for at least 2 hours and measure TR-FRET.

General Considerations

5

Assay Types

5.1 5.1.1 Endpoint Assay

The Transcreener® AMP²/GMP² TR-FRET Red Assay is designed for endpoint readout.

5.1.2 Real-Time Assay

This assay can be performed in real time by eliminating stop reagents and including the AMP/GMP Detection Mixture components (antibody and tracer) in the enzyme reaction. However, this mode should only be used for relative activity comparisons, because the extended signal equilibration time precludes accurate quantitation of AMP/GMP. A standard curve run under similar conditions (continuous mode) will help in extrapolating the FRET ratios to amount of AMP or GMP product formed.

Reagent and Signal Stability

- 5.2 The Transcreener® technology provides a robust and stable assay method to detect AMP/GMP.

5.2.1 Signal Stability

The stability of the TR-FRET ratio assay window at 10% substrate conversion was determined after the addition of the AMP/GMP Detection Mixture to the standard samples. The ratio assay window at 10% substrate conversion (10 μ M) remained constant (<10% change) for at least 24 hours at room temperature (20–25°C). If you plan to read TR-FRET on the following day, seal the plates to prevent evaporation.



5.2.2 AMP/GMP Detection Mixture Stability

It is important that the AMP/GMP Detection Mixture is prepared just prior to addition to the enzyme reaction. If you prepare the AMP/GMP Detection Mixture more than 30 minutes before addition, store it on ice or at 4°C until needed to help decrease the equilibration time.

5.2.3 Stopping the Reaction

We have inhibited the activity of several phosphodiesterases and ubiquitin ligases by the addition of Stop Buffer B (200 mM HEPES, 0.2% Brij®-35, and 400 mM EDTA [pH 7.5]), by quenching MgCl_2 with EDTA. This buffer can be purchased separately: Part #2027 (1 mL) or 2032 (10 mL)

Troubleshooting

6

Problem	Possible Causes and Solutions
Low selectivity	<i>Suboptimal tracer concentration</i> - To achieve maximum sensitivity and assay window, the AMP/GMP tracer concentration must be optimized for each starting ATP/cAMP/cGMP concentration. <i>ATP/cAMP/cGMP concentration out of range</i> - Ensure that the starting ATP/cAMP/cGMP concentration is in the range of 1–1,000 μM.
No change in TR-FRET observed	<i>Low antibody/tracer activity</i> - The tracer and antibody are stable for up to 6 freeze-thaw cycles. For frequent use, aliquot the antibody and tracer and store the aliquots at -20°C. Use a minimum of 20 μL aliquots. <i>Interference from metal ions</i> Mn^{2+} or heavy metals like Cu^{2+}, Fe^{2+}, Fe^{3+}, Cr^{3+}, or Co^{2+} can quench terbium at higher concentrations. This effect can be relieved by using an EDTA-containing stop buffer (see Section 5 "Stopping the Reaction"). Use a minimum molar ratio of at least 4X EDTA to metal ions.
High background signal or change in signal after incubation	<i>Nonspecific ATP/cAMP/cGMP hydrolysis</i> - Aliquot the stock solution of nucleotide or prepare it fresh each time to avoid frequent freeze-thaw cycles. <i>Interference from impurities</i> - Nuclease contamination in the buffer can cause the assay window to collapse, causing a change in FRET ratio. We recommend using nuclease-free water and freshly prepared buffer for each assay. - Some compounds may interfere with the detection mixture, causing a change in signal (see Section 7.2).

Problem	Possible Causes and Solutions
	Bovine serum albumin (BSA) at concentrations >1% interferes with the detection reagents. Detergents, such as Brij-35, can be substituted for BSA in the enzyme reaction to prevent nonspecific binding of enzymes and substrates to the plate.

Appendix

7

Standard Curves

- 7.1 A standard curve (**Figure 5**) is required to convert FRET ratios to product formation (AMP or GMP) for quantitative data analysis. Because the Transcreener® AMP²/GMP² TR-FRET Red Assay relies on a competitive binding reaction, the response is nonlinear, and therefore the signal is not directly proportional to reaction progress.

The wells for the standard curve should contain all AMP/GMP reaction components except the enzyme and receive AMP/GMP Detection Mixture. The curve is constructed to mimic an enzyme reaction: starting at the ATP/cAMP/cGMP concentration used for the screening reactions, ATP/cAMP/cGMP is decreased in increments and the AMP/GMP concentration is increased proportionally, keeping the sum of their concentrations [ATP/cAMP/cGMP + AMP/GMP] constant.

We recommend using a 12-point curve with concentrations of ATP/cAMP/cGMP and AMP/GMP corresponding to 0%, 0.5%, 1%, 2%, 3%, 5%, 7.5%, 10%, 15%, 30%, 50%, and 100% conversion (see **Table 1**). Allow 2-3 hours incubation prior to FRET measurement for complete equilibration.

% Conv.	ATP (μM)	AMP (μM)
100	0	100
50	50	50
30	70	30
15	85	15
10	90	10



	% Conv.	ATP (μ M)	AMP (μ M)
	7.5	92.5	7.5
	5	95	5
	3	97	3
	2	98	2
	1	99	1
	0.5	99.5	0.5
	0	100	0

Table 1. Concentrations of ATP/AMP to prepare a 12-point standard curve.




Figure 5. Standard curves. Data are shown for ATP to AMP (**A**), cGMP to GMP (**B**), and cAMP to AMP (**C**) standard curves for initial substrate concentrations of 0.1–100 μM in the 15 μL mock enzyme reaction. All assays were performed in 384-well plates ($n = 12$) and read on the Perkin Elmer EnVision multimode plate reader. Δ_{Ratio} is the change in TR-FRET 665:615 ratio from 0%.

D

	0.1 μ M Std Curve		1.0 μ M Std Curve		10 μ M Std Curve		100 μ M Std Curve	
	Z' at 30% Conversion	LLD (nM)	Z' at 10% Conversion	LLD (nM)	Z' at 10% Conversion	LLD (nM)	Z' at 10% Conversion	LLD (nM)
ATP:AMP	0.8	5	0.9	5	0.9	50	0.9	250
cGMP:GMP	0.7	7.5	0.7	10	0.8	50	0.9	250
cAMP:AMP	0.7	7.5	0.7	10	0.8	50	0.9	250

Figure 5. Standard curves (cont.) D) Z' values for initial velocity detection (10% conversion for 1 μ M, 10 μ M and 100 μ M ATP/ADP standard curves, 30% for 0.1 μ M) and lower limits of detection (LLD). LLD = the concentration of AMP/GMP that generates Z' >0.

Use the following equations to calculate the Z' factor:

$$\Delta \text{ratio} = \text{ratio}_{\text{initial [GTP]}} - \text{ratio}_{\text{sample}}$$

$$Z' = 1 - \frac{[(3 \times SD_{\text{initial [GTP]}}) + (3 \times SD_{\text{sample}})]}{|(\text{ratio}_{\text{initial [GTP]}}) - (\text{ratio}_{\text{sample}})|}$$

Summary of Additive Effects on the Transcreener® AMP²/GMP² TR-FRET Assay

- 7.2 The assay window at 10% substrate conversion remains constant (<10% change) when up to 10% DMSO, DMF, ethanol, acetonitrile, ethanol, or methanol are used in the enzyme reaction. Contact BellBrook Labs Technical Service for further reagent compatibility information.



Component	5-Hour Tolerance (0–100% Conversion Signal)	5-Hour Tolerance (0–10% Conversion Signal)
Solvents		
Acetonitrile	>50%	12.5%
DMSO	3.13%	3.13%
Ethanol	>50%	12.50%
Methanol	>50%	25.00%
Glycerol	>50%	0.39%
Detergents		
Brij-35	0.94%	0.47%
CHAPS	1.25%	0.08%
NP40	0.16%	0.16%
SDS	0.04%	0.04%
Triton X-100	0.31%	0.31%
Sodium deoxycholate	0.00%	0.16%
N-lauroyl sarcosine	0.08%	0.04%
Metal chelates		
EDTA	125 mM	62.5 mM
EGTA	>250 mM	125 mM
Reductants		
Beta mercaptoethanol	6.25%	0.02%
Dithiothreitol	>500 mM	0.031 mM

Component	5-Hour Tolerance (0–100% Conversion Signal)	5-Hour Tolerance (0–10% Conversion Signal)
Salts		
Ammonium acetate	125 mM	125 mM
Ammonium sulfate	3.91 mM	3.91 mM
Calcium chloride	15.62 mM	7.81 mM
Magnesium acetate	15.62 mM	3.91 mM
Magnesium chloride	15.62 mM	7.81 mM
Magnesium sulfate	1.95 mM	1.95 mM
Manganese chloride	15.62 mM	7.81 mM
Potassium chloride	500 mM	125 mM
Sodium azide	1.25%	1.25%
Sodium bromide	12.5 mM	3.12 mM
Sodium chloride	12.5 mM	6.25 mM
Phosphatase Inhibitors		
Glycerol phosphate	15.62 mM	7.81 mM
Imidazole	62.5 mM	62.5 mM
Sodium fluoride	7.81 mM	3.91 mM
Sodium molybdate	31.25 mM	31.25 mM
Sodium tartrate	>400 mM	200 mM
Sodium orthovanadate	7.81 mM	7.81 mM
Sodium pyrophosphate	0.39 mM	0.78 mM
Carrier Proteins/Coactivators		
BSA	>1.0 mg/mL	>1.0 mg/mL
BGG	>2.5 mg/mL	>2.5 mg/mL

Not all combination of these components have been tested together. Results may vary depending on your assay conditions.

Bibliography

- Antczak C, Shum D, Radu C, et al. Development and validation of a high-density fluorescence polarization based assay for the trypanosoma RNA triphosphatase TbCet1. *Comb Chem High Throughput Screen* 2009; 12(3): 258–268.

Huss KL, Blonigen PE, Campbell RM. Development of a Transcreener™ kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. *J Biomol Screen* 2007;12(4): 578–584.

Kleman-Leyer KM, Klink TA, Kopp AL, et al. Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay. *Assay Drug Dev Technol* 2009;7(1): 56–65.

Klink TA, Kleman-Leyer KM, Kopp AL, et al. Evaluating PI3 kinase isoforms using Transcreener™ ADP assays. *J Biomol Screen* 2008;13(6): 476–485.



Liu Y, Zalameda L, Kim KW, et al. Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP assay for high-throughput screening. *Assay Drug Dev Technol* 2007;5: 225–235.

Lowery RG, Kleman-Leyer KM. Transcreener™: screening enzymes involved in covalent regulation. *Expert Opin Ther Targets* 2006;10(1): 179–190.

Reifenberger JG, Pinghau G, Selvin PR. Progress in lanthanides as luminescent probes in *Reviews in Fluorescence*. Geddes CD, Lakowicz JR, eds. Vol. 2. 2005, Springer US, New York, pp 399–431.

Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* 2009; 4(2): 67–73.

Contact Information

9 **Email:** TechSupport@bellbrooklabs.com
 Phone: 608.443.2400
 Toll-Free: 866.313.7881
 FAX: 608.441.2967

Protocol references

Antczak C, Shum D, Radu C, et al. Development and validation of a high-density fluorescence polarization based assay for the trypanosoma RNA triphosphatase TbCet1. *Comb Chem High Throughput Screen* 2009; 12(3): 258–268.

Huss KL, Blonigen PE, Campbell RM. Development of a Transcreener™ kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. *J Biomol Screen* 2007;12(4): 578–584.

Kleman-Leyer KM, Klink TA, Kopp AL, et al. Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay. *Assay Drug Dev Technol* 2009;7(1): 56–65.

Klink TA, Kleman-Leyer KM, Kopp AL, et al. Evaluating PI3 kinase isoforms using Transcreener™ ADP assays. *J Biomol Screen* 2008;13(6): 476–485.

Liu Y, Zalameda L, Kim KW, et al. Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP assay for high-throughput screening. *Assay Drug Dev Technol* 2007;5: 225–235.

Lowery RG, Kleman-Leyer KM. Transcreener™: screening enzymes involved in covalent regulation. *Expert Opin Ther Targets* 2006;10(1): 179–190.

Reifenberger JG, Pinghau G, Selvin PR. Progress in lanthanides as luminescent probes in *Reviews in Fluorescence*. Geddes CD, Lakowicz JR, eds. Vol. 2. 2005, Springer US, New York, pp 399–431.

Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* 2009; 4(2): 67–73.